 | Up a level |
Journal Article
Golfmann, K., Meder, L., Tharun, L., Dietlein, F., Malcher, F., Koker, M., Buettner, R. and Ullrich, R. T. (2017). Targeting FGFR1 and VEGFR1 displays synergistic treatment effects in FGFR1 overexpressed breast cancer. Oncol. Res. Treat., 40. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262
Meder, L., Schuldt, P., Thelen, M., Dietlein, F., von Baildon, Bergwelt M., Reinhardt, C. and Ullrich, R. T. (2017). Dual inhibition of anti-VEGF and anti-PD-L1 displays synergistic treatment effects in a small cell lung carcinoma mouse model. Oncol. Res. Treat., 40. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262
Rabenhorst, A., Leja, S., Florin, A., Foerster, A., Heukamp, L. C., Ullrich, R. T., Willenborg, S., Eming, S., Buettner, R. and Hartmann, K. (2015). Mast cell-derived vascular endothelial growth factor contributes to tumor growth. J. Invest. Dermatol., 135. S. S19 - 1. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1523-1747
Rabenhorst, A., Leja, S., Florin, A., Heukamp, L. C., Ullrich, R. T., Foerster, A., Roers, A., Buettner, R. and Hartmann, K. (2015). Contribution of mast cell-derived VEGF to tumor growth. Exp. Dermatol., 24 (3). S. E33 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Rabenhorst, A., Leja, S., Florin, A., Heukamp, L. C., Ullrich, R. T., Foerster, A., Roers, A., Buettner, R. and Hartmann, K. (2015). Contribution of mast cell-derived VEGF to tumor growth. Exp. Dermatol., 24 (3). S. E33 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C. D., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., Guerreiro, A. da Palma, von Jan, J., Kisis, I., Wasserburger, E., Claasen, J., Faitschuk-Meyer, E., Altmueller, J., Nuernberg, P., Yang, T. -P., Lienhard, M., Herwig, R., Kreuzer, K. -A., Pallasch, C. P., Buettner, R., Schaefer, S. C., Hartley, J., Abken, H., Peifer, M., Kashkar, H., Knittel, G., Eichhorst, B., Ullrich, R. T., Herling, M., Reinhardt, H. C., Hallek, M., Schweiger, M. R. and Frenzel, L. P. (2022). Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood, 140 (20). S. 2113 - 2127. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Ullrich, R. T., Zander, T., Wolf, J. and Hallek, M. (2012). Personalised treatment of lung cancer. Dtsch. Med. Wochenschr., 137 (42). S. 2179 - 2181. STUTTGART: GEORG THIEME VERLAG KG. ISSN 0012-0472